China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products,… Read more
China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Total Assets
Latest total assets as of September 2025: CN¥56.56 Billion CNY
Based on the latest financial reports, China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) holds total assets worth CN¥56.56 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Total Assets Trend (1997–2024)
This chart illustrates how China Resources Sanjiu Medical & Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
China Resources Sanjiu Medical & Pharmaceutical Co Ltd's total assets of CN¥56.56 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.5% |
| Accounts Receivable | CN¥9.20 Billion | 23.0% |
| Inventory | CN¥4.93 Billion | 12.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥4.09 Billion | 10.2% |
| Goodwill | CN¥5.12 Billion | 12.8% |
Asset Composition Trend (1997–2024)
This chart illustrates how China Resources Sanjiu Medical & Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Resources Sanjiu Medical & Pharmaceutical Co Ltd's current assets represent 54.6% of total assets in 2024, a decrease from 83.6% in 1997.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2024, down from 17.2% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 1.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 23.0% of total assets.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of China Resources Sanjiu Medical & Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - China Resources Sanjiu Medical & Pharmaceutical Co Ltd generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, China Resources Sanjiu Medical & Pharmaceutical Co Ltd generates $8.40 in net profit.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.83 | 1.88 | 1.50 |
| Quick Ratio | 1.39 | 1.47 | 1.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥12.01 Billion | CN¥ 10.86 Billion | CN¥ 3.63 Billion |
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between China Resources Sanjiu Medical & Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | CN¥40.08 Billion |
| Market Capitalization | $2.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values China Resources Sanjiu Medical & Pharmaceutical Co Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: China Resources Sanjiu Medical & Pharmaceutical Co Ltd's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for China Resources Sanjiu Medical & Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual total assets of China Resources Sanjiu Medical & Pharmaceutical Co Ltd from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥40.08 Billion | -0.17% |
| 2023-12-31 | CN¥40.15 Billion | +48.02% |
| 2022-12-31 | CN¥27.12 Billion | +11.58% |
| 2021-12-31 | CN¥24.31 Billion | +10.44% |
| 2020-12-31 | CN¥22.01 Billion | +9.48% |
| 2019-12-31 | CN¥20.10 Billion | +11.50% |
| 2018-12-31 | CN¥18.03 Billion | +11.33% |
| 2017-12-31 | CN¥16.20 Billion | +19.51% |
| 2016-12-31 | CN¥13.55 Billion | +12.75% |
| 2015-12-31 | CN¥12.02 Billion | +12.67% |
| 2014-12-31 | CN¥10.67 Billion | +4.15% |
| 2013-12-31 | CN¥10.24 Billion | +18.93% |
| 2012-12-31 | CN¥8.61 Billion | +13.34% |
| 2011-12-31 | CN¥7.60 Billion | +24.76% |
| 2010-12-31 | CN¥6.09 Billion | +8.16% |
| 2009-12-31 | CN¥5.63 Billion | +11.48% |
| 2008-12-31 | CN¥5.05 Billion | -35.02% |
| 2007-12-31 | CN¥7.77 Billion | +10.19% |
| 2006-12-31 | CN¥7.05 Billion | +0.16% |
| 2005-12-31 | CN¥7.04 Billion | -1.87% |
| 2004-12-31 | CN¥7.18 Billion | -13.48% |
| 2003-12-31 | CN¥8.30 Billion | +21.11% |
| 2002-12-31 | CN¥6.85 Billion | +3.81% |
| 2001-12-31 | CN¥6.60 Billion | +12.04% |
| 2000-12-31 | CN¥5.89 Billion | +64.54% |
| 1999-12-31 | CN¥3.58 Billion | +109.73% |
| 1998-12-31 | CN¥1.71 Billion | +16.28% |
| 1997-12-31 | CN¥1.47 Billion | -- |